



## Guidelines for abstract submission

### General information

ESCAIDE 2024 will take place 20–22 November 2024 as a hybrid event in Stockholm and online. The standard abstract call will run from 17 April to 15 May. A late breaker abstract call will run from 12 to 23 September.

ESCAIDE 2024 welcomes abstracts in all areas applied to infectious disease and public health. These areas include epidemiology, microbiology, virology, immunology, social sciences, science communication, the application of tools and methods to support infectious disease interventions and more. We encourage submissions that inform public health actions, introduce new ideas, and bring new understandings to the field. Abstracts should be submitted in the form of text via the dedicated online platform:

<https://abstracts.escaideconference.eu/>

Submit an abstract

### Abstract submission process

**Requests for changes:** The submitting author is responsible for the content submitted: any error in spelling, grammar or scientific fact will be reproduced as typed by the author. Corrections to abstracts can be made by 15 May 2024 (23:59 CEST), directly in the submission platform. No requests for changes will be allowed after this date.

**Abstract ID number:** Successfully submitted abstracts will be acknowledged by email sent to the submitting author and the presenter (if different from the submitting author), with an abstract reference number, which should be quoted in all correspondence.

**Review and selection of abstracts:** Submitted abstracts will be reviewed by three independent reviewers and by the Scientific Committee (in cases where the selection algorithm cannot be applied, or where further judgement and a final decision is needed) to determine acceptance for presentation at ESCAIDE. For more information on the abstract selection process and review criteria, please read the dedicated [Guidelines for abstract review and selection ESCAIDE 2024](#).

**Communication of results:** Results of the abstract submission will be communicated to the submitting author and the presenter (if different from the submitting author), by email by 28 June. Accepted abstracts will be distributed in the programme and it is the responsibility of the presenter to check the date and time of the presentation, and to register to attend the conference.

### Submission form

**Create an account:** Fill in contact details (name, email, affiliation, etc.) of the submitting author for the abstract. The email address and password chosen here will be used to login to the abstract submission platform to create, edit and submit abstract(s). Please note that this email address must be the same one that will be used when registering for the conference.

**Submission tracks:** Each abstract should be tagged with a disease group and a health function that best match the content of the abstract. This is important as the tracks will be used to allocate the abstract to the correct reviewers, i.e., experts in the selected topics.

Disease groups	Health functions
<ul style="list-style-type: none"> <li>● Antimicrobial resistance</li> <li>● COVID-19</li> <li>● Healthcare-associated infections</li> <li>● Emerging and vector-borne diseases</li> <li>● Food- and waterborne diseases and zoonoses</li> <li>● HIV, STI and viral hepatitis</li> <li>● Respiratory viruses and diseases</li> <li>● Public health sciences (general)</li> <li>● Vaccine preventable diseases</li> </ul>	<ul style="list-style-type: none"> <li>● Burden of disease</li> <li>● Social and behavioural sciences</li> <li>● Field epidemiology (e.g., outbreak investigation)</li> <li>● Implementation science (e.g., integration of research findings and evidence into public health policy and practice; evaluation of interventions)</li> <li>● International health and migration</li> <li>● Mathematical modelling, bioinformatics, biostatistics, and foresight</li> <li>● Microbiology</li> <li>● Novel methods (e.g., digital disease detection, e-health)</li> <li>● Preparedness</li> <li>● Surveillance</li> </ul>

**Title:** Choose a title that reflects the main message of the content. Acronyms should be avoided, as they may be unclear to some readers. Refrain from capitalising the entire title or beginning each word with a capital letter, as this can make the title difficult to read.

**First author & co-authors:** The submitting author will by default be added as the first author, but this can be changed if it is not the case. The authors will be listed in the order you enter them. If your abstract has multiple co-authors, please fill in all the required fields for each author. The co-authors will be listed in the order that you enter them.

**Affiliations:** When listing affiliations for authors, please only include the primary organisations they are affiliated with. If an author has multiple affiliations, please list them without numbering as the system will automatically organise them. To add affiliations, please use the format 'Full organisation name (Abbreviation)'. For example, 'European Centre for Disease Prevention and Control (ECDC)'. If you are a currently a fellow in a training programme, please include a separate affiliation with the name and abbreviation of the programme. For example, 'Finnish Institute for Health and Welfare (THL)' and 'European Programme for Intervention Epidemiology Training (EPIET)'.

**Consortium, network or group:** If the abstract is co-authored by a consortium, network or group, please do not list all the co-authors and just give the name of the consortium, network or group.

**Presenter:** The submitting author will by default be added as the presenter, but this can be changed if it is not the case. Fill in the details of the person who will present the abstract at the conference. This is very important, as their name will be included in the programme and in the abstract book. The presenter of an accepted abstract must register and attend the conference to ensure the presentation of the abstract. Please note that the email address entered must be the same one that will be used when registering for the conference.

**Keywords:** Please include 4-6 key words; use terms listed in the Medical Subject Headings (MeSH) from the Index Medicus (<http://www.nlm.nih.gov/mesh/>).

**Abstract background, methods, results and conclusions:** The total text should **not exceed 275 words**. Abstracts must be submitted in English using UK English spelling. Please do not repeat the headings 'background', 'methods', 'results' or 'conclusions'. Follow the structure proposed and take advantage of the guiding questions as they will also be used by the reviewers when assessing your abstract. For the full list of assessment criteria that will be used by reviewers, please see the [Guidelines for abstract review and selection ESCAIDE 2024](#).

**Disclosure of the use of Generative AI tools in the abstract:** Given the rise of the use of Generative AI tools in scientific research and writing, and to ensure transparency and maintain the integrity of submissions, we are asking abstract authors to disclose any use of such tools in the production of their abstract, and to take full responsibility for the content of their abstract. Please note this information will not be shared with the reviewers, but the Scientific Committee reserves the right to exclude any abstract that is based on research conducted or generated *solely* by AI tools.

**Declaration of originality:** As a principle, ESCAIDE abstracts should contain original material from recent work that is not yet in the public domain or has not been presented at other conferences. Abstracts of published work are discouraged, as is the submission of the same abstract to multiple conferences. However, there may be cases where an abstract with previously published or presented work can still provide value to the ESCAIDE audience due to its public health significance. Whether to accept such an abstract is left at the discretion of the reviewers and Scientific Committee, and priority will be given to original content of high public health significance. If the abstract contains previously published or presented material, the author must disclose this information in the 'Declaration of originality' field and include a link to the publication if applicable.

**Preferred presentation method:** The Scientific Committee will decide on the final presentation format, but you can indicate your preference for 'Oral presentation' or 'Poster presentation'. In the 'Oral' format, presenters will be invited to present a short summary and discuss their work in a Q&A session. If you select 'Poster presentation only', it means that your abstract will be considered only for poster presentation. In this format, posters are submitted in advance on a dedicated platform. During the conference they will be displayed on screens (e-poster terminals) in the venue, and the presenter will briefly introduce the abstract and take questions during the Poster tour they are assigned to. Please note that if your abstract is selected as a Poster presentation, the presenter will need to attend the conference in-person, as remote poster presentations will not be possible. Similarly, this year there are no options for 'online posters only'.

**Presenter plans to attend:** Please indicate your preference for presenting in-person or remotely. **Abstracts selected for oral presentations have the option for remote presentation.** However, we encourage on-site presentations when possible. Presenting in-person enhances networking opportunities and simplifies the integration of online and in-person presentation formats. **Poster presentations are limited to in-person participation only.** If your abstract is accepted for a poster presentation and you are unable to attend in person, you may nominate a co-author to present on your behalf. Please ensure that the nominated presenter is able and willing to attend in person. If a substitute presenter cannot be arranged, the abstract will unfortunately have to be withdrawn from the conference.

## Important dates

**Call for abstracts:** 17 April–15 May

**Review period:** 17 May–3 June

**Communication of results to authors:** by 28 June

**Call for late breakers:** 12 September–23 September

**Late breakers review period:** 25 September–7 October

**Communication of late breaker results to authors:** by 18 October

**ESCAIDE 2024:** 20–22 November

## Opportunities for funding

**Are you an early career researcher residing in the EU/EEA?** The ESCAIDE Funding Initiative provides financial support for the attendance of selected abstract presenters. To determine if you meet the eligibility criteria, please review the criteria on our website before indicating that you are eligible in the abstract submission form. Applicants who express interest will be contacted later to provide additional information. Please note that funding is only available to presenters whose abstracts are accepted. [Find out more about the ESCAIDE Funding Initiative.](#)